Effect of some antipsychotic drugs on immunoreactivity in C57BL/6 mice

Polish Journal of Pharmacology

Volumn 54, Issue 6, 2002, Pages 737-742

  Basta Kaim, Agnieszka ^a   Kubera, Marta ^a   Budziszewska, Bogusława ^a   Siwanowics, Joanna ^a   Lasoń, Władysław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chlorpromazine; Clozapine; Proliferative and metabolic activity of splenocytes; Sulpiride

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CONCANAVALIN A; DOPAMINE 2 RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; NEUROLEPTIC AGENT; POKEWEED MITOGEN; SULPIRIDE; THYMIDINE; TRITIUM;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL LABELING; CELL METABOLISM; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; DRUG POTENCY; IMMUNE SYSTEM; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PSYCHOSIS; SPLEEN CELL;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; SPLEEN;

EID: 0036970983     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Baker G.A., Santalo R., Blumenstein J.: Effects of psychotropic agents upon the blastogenic response of human T-lymphocytes. Biol. Psychiat., 1997, 12, 159-169.
2. Basta-Kaim A., Budziszewska B., Jaworska-Feil L., Tetich M., Leśkiewicz M., Kubera M., Lasoń W.: Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium-dependent manner. Neuropharmacology, 2002, 43, 1035-1043.
3. Boukhris W., Kouassi E., Revillard J.P.: Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol. Immunotoxicol., 1998, 10, 501-512.
4. Descotes J., Tedone R., Evreux J.C.L.: Different effects of psychotropic drugs on delayed hypersensitivity responses in mice. J. Neuroimmunol., 1985, 9, 81-85.
5. Ferguson R.M., Schmidtke J.R., Simmons R.L.: Concurrent inhibition by chlorpromazine of concanavalin-A induced lymphocyte aggregation and mitogenesis. Nature, 1975, 256, 744-745.
6. Hinze-Selch D., Becker E.W., Stein G.M., Berg P.A., Mullington J., Holsboer F., Pollmacher T.: Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology, 1998, 19, 114-122.
7. Kubera M., Basta-Kaim A., Skowron-Cendrzak A., Mazur-Kolecka B., Roman A., Borycz J.: Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity. Pol. J. Pharmacol., 1995, 47, 321-326.
8. Kubera M., Cyrul W., Basta-Kaim A., Budziszewska B., Leśkiewicz M., Holan V.: Effect of repeated desipramine and fluoxetine administration on post-adjuvant arthritis. Pol. J. Pharmacol., 2000, 52, 229-235.
9. Leykin I., Mayer R., Shinitzky M.: Short- and longterm immunosuppressive effects of clozapine and haloperidol. Immunopharmacology, 1997, 37, 75-86.
10. Maes M., Bosmans E., Kenis G., DeJong R., Smith R.S., Meltzer H.Y: In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res., 1997, 26, 221-225.
11. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., DeLey M., Bergmans R., Stans G., Desnyder R.: Lower plasma CC16, a natural anti-inflammatory protein and increased plasma interleukin-1-receptor-antagonist in schizophrenia. Schizophr. Res., 1996, 21, 39-50.
12. Maes M., Meltzer H.Y, Bosmans E.: Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiat. Scand., 1994, 89, 346-351.
13. Masserini C., Vita A., Basile R., Morselli R., Boato P., Peruzzi C., Pugnetti L., Ferrante P., Cazzullo C.L.: Lymphocyte subsets in schizophrenic disorders. Relationships with clinical, neuromorphological and treatment variables. Schizophr. Res., 1990, 3, 269-275.
14. Muller N., Hofschuster E., Ackenheil M., Eckstein R.: T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiat. Scand., 1993, 87, 66-71.
15. Nyland H., Naess A., Lunde H.: Lymphocyte subpopulations in peripheral blood from schizophrenic patients. Acta Psychiat. Scand., 1980, 61, 313-318.
16. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenetic mechanism. J. Clin. Psychiat., 1994, 55, 143-148.
17. Rapaport M.H., McAllister C.G., Kirch D.G., Pickar D.: The effect of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol. Psychiat., 1990, 29, 715-717.
18. Roudebush R.E., Berry P.L., Layman N.K., Butler L.D., Bryant H.U.: Dissociation of immunosuppression by chlorpromazine and trifluoroperazine from pharmacologic activities as dopamine antagonists. Int. J. Immunopharmacol., 1991, 13, 961-968.
19. Roufogalis B.D., Minoherhomjee A.M., Al-Jarobe A.: Pharmacological antagonism of calmodulin. Can. J. Biochem. Cell. Biol., 1983, 61, 927-930.
20. Rzewuska M.: Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature.(Polish), Psychiat. Pol., 1998, 32, 655-666.
21. Schleuning M.J., Duggan A., Reem G.H.: Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur. J. Immunol., 1989, 19, 1491-1496.
22. Song C., Lin A., Kenis G., Bosmans E., Maes M.: Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res., 2000, 42, 157-164.
23. Sugerman A.A., Southern D.L., Curran J.F.: A study of anibody levels in alcoholic, depressive and schizophrenic patients. Ann. Allergy, 1982, 48, 166.
24. Wilke I., Arolt V., Rothermundt M., Weitzsch Ch., Hornberg M., Kirchner H.: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiat. Clin. Neuros., 1996, 256, 279-284.